EVEREST MED (01952) Welcomes Two Top mRNA Talents to Accelerate the Implementation of Its Global Innovation Strategy

On October 9, EVEREST MED (01952) announced the appointment of Dr. Lakshmi Srinivasan as Senior Vice President and Head of Translational Medicine, and Dr. Brandon Coder as Vice President of Translational Science and Early Research. These appointments will further strengthen the global R&D capabilities and international collaboration layout of EVEREST MED's mRNA technology platform. In the future, the company will continue to gather top international talent, integrate R&D resources, and accelerate the implementation of its global innovation strategy. Both newly appointed executives possess deep industry experience and professional backgrounds. They previously oversaw oncology vaccine R&D at globally leading biopharmaceutical companies such as Moderna, and have complete hands-on experience spanning early discovery, clinical translation, and clinical development. Under the leadership of EVEREST MED's management, these two senior scientists will focus on advancing the clinical development of the company's mRNA technology platform in the United States and related business layout, in line with the company's global mRNA R&D strategy, while working closely with the China R&D team to further empower the evolution of the mRNA technology platform. Wu Yifang, Chairman of the Board of EVEREST MED, stated that he is very pleased to welcome Dr. Srinivasan and Dr. Coder to EVEREST MED. The two senior scientists possess deep experience in oncology vaccine R&D, translational medicine, and clinical development, which will further strengthen the company's global mRNA R&D capabilities and help advance the global clinical development of its proprietary mRNA technology platform and related product pipelines. These appointments reflect EVEREST MED's commitment to continuously gathering top global talent and advancing its global mRNA strategy. As one of the few biopharmaceutical companies globally with a full-process, independently controllable mRNA technology platform, EVEREST MED has built a complete industrial chain platform covering antigen design, mRNA sequence optimization, lipid nanoparticle (LNP) targeted delivery technology, and industrial-scale production. It possesses end-to-end capabilities across the mRNA platform value chain and has successfully achieved clinical validation.